- US-listed companies
- PTC THERAPEUTICS, INC.
- Income statement
PTC THERAPEUTICS, INC. (PTCT) Income statement
Market cap
$5.9B
P/E ratio
9.2x
| 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 35 | 25 | 37 | 83 | 194 | 265 | 307 | 381 | 539 | 699 | 938 | 807 | 1,731 |
| Revenue growth (%) | - | ||||||||||||
| Cost of revenue | - | - | - | - | 5 | - | 12 | - | - | - | - | - | - |
| Research & development | 55 | 80 | 122 | 118 | 117 | 172 | 257 | 478 | 541 | 651 | 667 | 534 | 455 |
| Selling, general & administrative | - | - | - | - | - | 154 | 203 | 245 | 286 | 326 | 333 | 301 | 347 |
| Operating margin (%) | |||||||||||||
| Operating expenses | 80 | 125 | 204 | 215 | 259 | 380 | 548 | 813 | 913 | 1,146 | 1,377 | 1,109 | 864 |
| Operating income | -45,397,469 | -99 | -167 | -132 | -64 | -116 | -241 | -432 | -374 | -447 | -440 | -303 | 867 |
| Income before tax | -51,573,575 | -98 | -170 | -142 | -78 | -128 | -240 | -403 | -518 | -587 | -696 | -363 | 697 |
| Pretax margin (%) | -148.6 | -390 | -462.3 | -171.1 | -40 | -48.4 | -78.2 | -105.8 | -96.2 | -84.1 | -74.2 | -45 | 40.3 |
| Provision for income taxes | - | -5 | 0 | 1 | 1 | -0 | 12 | 35 | 6 | -28 | -70 | 0 | 14 |
| Effective tax rate (%) | - | ||||||||||||
| Net income | -51,573,575 | -94 | -170 | -142 | -79 | -128 | -252 | -438 | -524 | -559 | -627 | -363 | 683 |
| Net income margin (%) | |||||||||||||
| Earnings per share | -5.18 | -2.97 | - | - | - | - | - | - | -7.43 | -7.79 | -8.37 | -4.73 | 8.58 |
| Diluted EPS | -5.18 | -2.97 | - | - | - | - | - | - | -7.43 | -7.79 | -8.37 | -4.73 | 7.78 |
| EBITDA | - | - | - | - | |||||||||
| EBITDA margin (%) | - | - | - | - |